#ivd market 2019

[aishavass]

The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...

[maryharrisk5]

Recent study published by Adroit Market Research on Global in vitro diagnostics (ivd) market evaluates the market demand and forecast based on various forecasting models.

[evonnebaker]

The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several developing economies to tackle growing healthcare needs. Molecular diagnostics have emerged as one of the leading and fastest-growing sectors of the IVD industry

[cailynnjohnson]

From Lab-on-a-Chip to Industrial Innovation: Milestones in Microfluidic Technology

The global market for microfluidic products surged to $9.98 billion in 2019, with microfluidic devices accounting for $3.48 billion of this figure. A notable trend in the industry is the ongoing acquisition of microfluidic companies by larger enterprises, signaling a trajectory of accelerated growth through capital infusion.

In the industrial landscape, in vitro diagnostics (IVD) stands out as the primary sector for microfluidic applications, driven by its lucrative returns. Demographic shifts, particularly aging populations, contribute to an escalating demand for microfluidic chips. Moreover, governmental policies prioritize the advancement of the microfluidics industry, a focus that has intensified amidst the backdrop of the pandemic. Moving forward, the critical hurdles facing microfluidic chip technology revolve around manufacturing costs and scalability. Achieving scalable production processes and cost reduction measures while maintaining product standardization and minimizing variations are imperative objectives.

The evolution of modern technology emphasizes miniaturization, integration, and intelligence. Microelectromechanical systems (MEMS) have played a pivotal role in this evolution, enabling the transition from bulky electronic systems to compact integrated circuit chips and handheld devices like smartphones. Similarly, microfluidic chips, often referred to as Lab-on-a-Chip technology, epitomize the manipulation of fluids at micro- and nanoscales. These chips condense essential laboratory functionalities, such as sample preparation, reaction, separation, and detection, onto a compact chip, typically a few square centimeters in size. The hallmark of microfluidic chips lies in their capacity for flexible integration and scaling of diverse unit technologies within a controllable microplatform.

Originating from MEMS technology, early microfluidic chips underwent fabrication processes on substrates like silicon, metals, polymers, glass, and quartz. These processes yielded microstructure units such as fluid channels, reaction chambers, filters, and sensors, with dimensions ranging from micrometers to sub-millimeters. Subsequent fluid manipulation within these microstructures enabled automated execution of biological laboratory procedures, including extraction, amplification, labeling, separation, and analysis, or cell manipulation and analysis.

In the early 1990s, A. Manz et al. demonstrated the potential of microfluidic chips as analytical chemistry tools by achieving electrophoretic separation—a technique previously confined to capillaries—on chips. Subsequently, spurred by the U.S. Department of Defense's requisition for portable biochemical self-test equipment, research in microfluidic chips burgeoned globally. Throughout the 1990s, microfluidic chips primarily served as platforms for analytical chemistry, often interchangeably referred to as "Micro Total Analysis Systems" (u-TAS). Consequently, these chips found applications across diverse fields, including biomedical diagnostics, food safety, environmental monitoring, forensics, military, and aerospace sciences.

Key milestones in the advancement of microfluidic chips include G. Whitesides et al.'s 2000 publication on PDMS soft lithography and S. Quake et al.'s 2002 article on "large-scale integration of microfluidic chips" featuring microvalve and micropump controls. These seminal works propelled microfluidic chips beyond the confines of traditional analytical systems, unlocking their potential for significant scientific and industrial applications. For instance, microfluidic chips enable the execution of combinatorial chemical reactions or droplet techniques, facilitating drug synthesis, high-throughput screening, and large-scale nanoparticle or microsphere production. In essence, microfluidic chips pave the way for the realization of a "chemical plant or pharmaceutical lab on a chip."

[iso-updates]

Navigating the Transition: Understanding the UKCA Marking Certification Process for Medical Devices

The United Kingdom’s choice to leave the European Union has achieved tremendous changes, not just in that frame of mind of exchange and guidelines, but in addition to the accreditation processes governing the conformity of products. One pivotal part of this change is the entry of the UKCA (UK Conformity Assessed) marking, which replaces the CE marking for merchandise put on the UK market.

In this article, we will dig into the UKCA Marking in UAE certification process, giving bits of knowledge to assist organizations with exploring this basic change.

Scope and Applicability

Understanding whether an item requires UKCA marking is the most important phase in the certificate process. Not all products are dependent upon the new guidelines, and organizations should cautiously evaluate the particular necessities appropriate to their products. Certain items might in any case utilize CE marking, assuming that they are being sold in the EU and meet European guidelines.

What is UKCA Marking?

The United Kingdom Conformity Assessment Mark or UKCA Mark for short is what could be compared to the EU CE marking. UKCA Mark is a substantial pointer that a medical device adjusts to significant UK Guidelines. The United Kingdom Conformity Assessment marking is required for medical devices sold available in Great Britain (Britain, Wales, and Scotland).

United Kingdom’s Medicines and Health Care Products Regulatory Agency (MHRA) On 18 September 2019, distributed new rules to direct medical devices after Brexit. The UKCA won't be perceived in the EU, EEA, or Northern Ireland items actually require a CE marking available to be purchased in these business sectors.

The maker or their approved delegate will be answerable for fastening the UKCA Certification to the product, which is a similar rule concerning CE marking yet for the UK market.

What is UKCA Marking for Medical Devices?

The UKCA marking is a logo that implies a medical device's compliance with the UK MDR 2002 requirements. This mark certifies that the device is protected, fit for its planned reason, and conforms to the regulations connected with safety. It is a compulsory necessity for medical devices planned for the Great Britain market, which incorporates Britain, Wales, and Scotland.

Who Needs UKCA Marking for Medical Devices?

In the event that you are associated with the assembling, delivery, or import of medical devices in the UK, you might be expected to acquire UKCA marking. This incorporates:

Medical device makers situated in the UK

Merchants of medical devices in the UK

Organizations importing medical devices into the UK

Technical Documentation and Standards

The core of the certificate process lies in the preparation & accommodation of technical documentation. Makers should order an exhaustive record framing the item's plan, details, and conformity with significant UKCA Marking standards. Experience with these norms is significant, and organizations might have to adjust their cycles to meet the particular measures set by UK specialists.

Documentation Required for UKCA Certification: 

Records

Formats

Forms

Checklist

Standard Operating Procedure (SOP)

Plant Master File

Mission & Vision

Objectives

Policy

System Procedure

System Manual

Product Testing

Technical File, Product Master File (TCF)

The extent of Documented Information differs as per:

Notify body Certificate

Self Certification or Compliance Certification

Directive in which product classified

Testing requirements of products

Product and its uses

Key Requirements for Placing Medical Devices in the Great Britain Market:

New Product Marking (UKCA Mark): Guarantee that your medical device delivers the UKCA mark.

Registration with MHRA:: Every single medical device and IVD should be enrolled with MHRA before they can be made available.

UK Responsible Person: In the event that you are a producer situated external the UK, you should select a single UK-reliable individual.

Classification: Medical devices in the UK are classified as Class I, Class IIa, Class IIb, and Class III, like the European Union’s plan. Class I devices are generally safe, while Class III devices are high-risk.

Registration Process for Medical Devices (UKCA Marking Process)

The Medicines and Healthcare Products Regulatory Agency is the UK's regulatory power answerable for guaranteeing that meds and medical devices are protected and compelling.

Classification: Decide the order of your medical device as indicated by the MDR.

Conformity Assessment: Lead a conformity evaluation to show that your device meets security and execution requirements.

Specialized Documentation: Get ready tech documentation that incorporates device depictions, planned use, and medical information.

Application Submission: Present your application to the MHRA through the Medical Devices Information System (MDIS).

Assessment: MHRA will assess your application and specialized documentation to guarantee compliance with safety and execution prerequisites.

Registration Certificate: In the event that your application is effective, MHRA will give an enrollment declaration, permitting you to sell your medical device in the UK.

Additional Points:

A progress period exists for certain item products, permitting the utilization of existing CE marking until Dec. 12, 2027.

The particular process can shift contingent on your item type and intricacy.

Conclusion: A Roadmap for Compliance

Exploring the UKCA Marking in UAE certification process requires a key and informed approach. Organizations should put time and assets into understanding the subtleties of the new regulatory scene, guaranteeing that their items fulfill the expected guidelines for the UK market.

As the business climate keeps on developing, remaining adaptable and receptive to changes will be vital to keeping an upper hand and guaranteeing continuous admittance to the UK market. By embracing the UKCA marking process for medical devices as a chance for development and compliance, organizations can unhesitatingly explore the change and secure their situations in the post-Brexit time.

[delvenservices]

Microfluidics Market Regional & Demand Analysis

Microfluidics Market by Product (Devices, Components (Chip, Sensor, Pump, Valve)), Application (IVD (POC, Clinical, Veterinary), Research, Manufacturing, Therapeutics), End User (Hospital, Diagnostic Center, Academic Institutes), and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

The Microfluidics Market size is projected to reach a CAGR of 24.6% from 2022 to 2028.

Microfluidics is a medical approach involving the precise control of small fluid samples for medical analysis. The sample sizes in microfluidics range from microliters to picolitres. At such low volumes, the transportation of fluid is governed significantly by its mass.

Growing technological advancements in diagnostic devices, rising demand for microfluidics technology, and rising incidence of chronic diseases are some of the factors that have supported long-term expansion for Microfluidics Market.

The COVID-19 pandemic has impacted the overall microfluidics industry in positive ways. The demand for rapid diagnostic tests, POC tests, and IVD devices with microfluidic technology utilized in drug discovery and COVID-19 testing has witnessed a significant demand.

Get a Sample Copy of the Report:https://www.delvens.com/get-free-sample/microfluidics-market-trends-forecast-till-2028

Regional Analysis

North America is expected to account for the largest share of the microfluidics market. North America has various additional advantages—investment initiatives by governments and the presence of high-quality infrastructure for clinical and laboratory research.

Key Players

uFluidix

Bio-Rad Laboratories Inc.

Fluidigm Corporation

Illumina Inc.

PerkinElmer, Inc

Parker Hannifin Corporation

IDEXX Corporation

Fluigent SA

Aignep S.P.A.

Camozzi Automation SPA Societá Unipersonale

Dolomite microfluidics

To Grow Business Revenue, Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/microfluidics-market-trends-forecast-till-2028

Recent Developments

In March 2020, Parker-Hannifin Corporation (US) launched the LM-Pro linear motor proportional valves for the ventilators market.

In March 2020, Bio-Rad Laboratories Inc. (US) launched the SARS CoV-2 Standard to support laboratory assay validation of COVID-19 testing Germitec S.A. (France) received approval for the UV reprocessor from the FDA in April 2019.

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Microfluidics Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Get Direct Order of the Report: https://www.delvens.com/checkout/microfluidics-market-trends-forecast-till-2028

Report Scope

Microfluidics Market is segmented into type, application, end user and region.

On the basis of Type

Microfluidic-based devices

Microfluidic Components

On the basis of Application

In-vitro diagnostics

Pharmaceutical & Life Science Research and Manufacturing

Therapeutics

On the basis of End-User

Hospitals & Diagnostic Centers

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

Read More:

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

        SALES@DELVENS.COM

[healthcaremarketfmi]

Anatomic Pathology Market Detailed Survey On Key Trends, Leading Players & Revolutionary Opportunities 2030

The global anatomic pathology market forecast is set to reach US$ 61.1 Mn in revenues by 2030, according to a new market study by ESOMAR-certified market research firm, Future Market Insights (FMI).

The anatomic pathology market is subject to integrating medical informatics standards to meet specific healthcare requirements by curtailing costs and improvising on efficiency.

Pathology laboratories are on the verge of refurbishment as new-fangled disease diagnostic models are making a beeline therein.

As of now, lymphoma, breast cancer, colorectal cancer, prostate cancer, cervical cancer, and lung cancer are a part of anatomic pathology.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12370

Key Takeaways

The instruments are subject to technological advancements, which would minimize errors. This factor is expected to drive the anatomic pathology market between 2022 and 2030

Consumables are expected to hold the largest market share due to low cost, high availability, and good purchase rate of probes and reagents

Academic research is bound to pick up pace in the forecast period owing to growing implementation of anatomic pathology in biomarker profiling and tumor examination

Preference to personalized therapies is prompting putative biomarkers being discovered. This factor is expected to be one of the key growth drivers

Key Participant Insights

The key market players are focusing on technological upgradations and expansion strategies to keep themselves fiercely competitive.

For instance –

In Jul 2020, Bio SB tabled its Fast Mohs PolyDetector Plus Detection System, which comes across as a super sensitive nonbiotin monovalent Fab micropolymer immunohistochemistry system to detect IVD antibodies for squamous cell carcinoma, basal cell carcinoma, and melanoma.

In Jan 2019, Quest Diagnostics announced completion of acquisition of the US laboratory services business that belonged to Oxford Immunotec (the T-Spot and Accutix tick-borne disease testing services, since then, are part of Quest’s infectious disease testing services.

In 2018, Leica Microsystems entered into a collaboration with Thermo Fisher to develop an integrated cryotomography workflow with regards to research.

Expand operations in the future – To get requisite details, ask for a custom report@ https://www.futuremarketinsights.com/customization-available/rep-gb-12370

The other players in the veterinary imaging market include

Laboratory Corporation of America Holdings

Sakura Finetek USA, Inc.

F.Hoffmann-La Roche AG

Cardinal Health, Inc.

BioGenex

NeoGenomics

Agilent Technologies

The US continues to be one of the leading markets for anatomic pathology market globally. Strong presence of some of the leading players, combined with relatively easier funding for R&D will drive the US anatomic pathology market during the assessment period.

The Europe anatomic pathology market is also likely to grow at a brisk pace during the assessment period. The growth will remain concentrated in Western Europe, as has been the case traditionally.

Asia Pacific represents a high growth market for anatomic pathology stakeholders. Many countries in the region are renewing their focus on healthcare, as the current Covid-19 crisis has reinforced the necessity of a robust healthcare system.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global anatomic pathology market is segmented in detail to cover every aspect and present a complete market intelligence approach to the reader.

The study provides compelling insights on anatomic pathology market on the basis of product & services type (Instruments (Microtomes & Cryostat, Tissue processors, Automatic Stainers, and Other products), consumables (Reagents & Antibodies, Probes & Kits, and Others), application (Disease Diagnosis, Drug Discovery and Development, and Others), and services (histopathology, cytopathology)) across seven geographies.

[chemicaltech]

in vitro diagnostics quality control Market Pegged for Robust Expansion by 2031 | Type, Application, Scope & Key Companies

The global in vitro diagnostics quality control market was valued at USD 1.5 billion in 2021 and it is anticipated to grow further up to USD 2.2 billion by 2031, at a CAGR of 3.7% during the forecast period.

The effectiveness of in vitro diagnostic tests, including those for pathogen identification using in vitro nucleic acid testing, healthcare-associated illnesses (HAIs) such as pneumonia, urinary tract infections, and others, is assessed using IVD quality controls. These products primarily concentrate on defect detection, quality control, and validation panels like the Blood Culture (BCID) Control Panel, Human Papillomavirus (HPV) Control Panel, and others to support in the implementation and monitoring of the performance of clinical and research laboratories, blood diagnostic centers, and IVD manufacturers.

To Remain 'Ahead' Of Your Competitors, Request for A Sample – https://www.globalinsightservices.com/request-sample/GIS10301

Major Players in the Global In Vitro Diagnostic Quality Control Market

The key players studied in the global in vitro diagnostic quality control market are Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), and Helena Laboratories Corporation (US) among others.

Global In Vitro Diagnostics Quality Control Market Segmentation

By Product & Service

 Quality Control Products

Data Management Solutions

Quality Assurance Services

By Technology

 Immunochemistry

Clinical Chemistry

Molecular Diagnostics

Microbiology

Hematology

Coagulation/Hemostasis

Market Trends and Drivers

As the burden of various diseases increases globally, so has the number of laboratory tests. The number of laboratories in both the public and private sectors has increased in response to this need. With the start of the COVID-19 pandemic in December 2019, the demand for diagnostic tests has skyrocketed. Many government organizations have established new laboratories in response to this epidemic and to increase laboratory testing capacity. The majority of nations need clinical laboratories to get regulatory body accreditation before performing diagnostic tests. Additionally, accreditation to ISO 15189:2012 and other comparable standards is turning into a requirement in many nations. Authorities assess a laboratory’s competency and quality system during the accreditation process using predetermined standards. While some European nations, including Belgium, France, Hungary, Ireland, and Lithuania, require accreditation for a variety of laboratory tests, others, like Finland, the Netherlands, Sweden, Switzerland, and the UK, have practically finished the process.

With Global Insight Services, you receive:

·         10-year forecast to help you make strategic decisions

·         In-depth segmentation which can be customized as per your requirements

·         Free consultation with lead analyst of the report

·         Excel data pack included with all report purchases

·         Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm

headquartered in Delaware, US. We are committed to providing our clients

with highest quality data, analysis, and tools to meet all their market research

needs. With GIS, you can be assured of the quality of the deliverables, robust

and transparent research methodology, and superior service.

 Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

[aishavass]

The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...

[deshpandeisha]

The Future of Medical Device Outsourcing: Trends and Innovations

The global medical device outsourced manufacturing market size was USD 33.38 Billion in 2022 and is expected to register a revenue CAGR of 13.6% during the forecast period, according to the latest analysis by Emergen Research. Rising prevalence of chronic diseases such as diabetes and cardiovascular disease, rapid technological advancements in the product development of medical devices, and increased funding and investments toward early-stage medical technology-based startup companies are some of the key factors driving revenue growth of the medical device outsourced manufacturing market.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1760

Competitive Terrain:

The global Medical Device Outsourced Manufacturing industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Eakin Surgical., IQVIA., SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA., Eurofins Scientific, Bio-Rad Laboratories, Inc., Intertek Group plc, Charles River Laboratories, WuXi AppTec, Nipro Corporation, and Johari Digital

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Medical Device Outsourced Manufacturing market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Medical Device Outsourced Manufacturing market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Medical Device Outsourced Manufacturing market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1760

Market Segmentations of the Medical Device Outsourced Manufacturing Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Medical Device Outsourced Manufacturing market on the basis of product, application, and region:

Segments Covered in this report are:

Device Type Outlook (Revenue, USD Billion; 2019-2032)

IVD Devices

Drug Delivery Devices

Diabetes Care Devices

Cardiovascular Devices

Diagnostic Imaging Devices

Surgical Devices

Others

Service Type Outlook (Revenue, USD Billion; 2019-2032)

Prototyping Development services

Pilot Production services

Device manufacturing services

Injection molding

CNC Machining and Laser Cutting & 3D Printing

Cleaning and Finishing

Others

Quality Management Services

Packaging Validation services

Inspection and Testing Services

Sterilization services

Others

Class of Medical Device Outlook (Revenue, USD Billion; 2019-2032)

Class I

Class II

Class III

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/medical-device-outsourced-manufacturing-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1760

[smithwillblog]

Vitro Diagnostics (IVD) Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026

Vitro Diagnostics (IVD) Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026

Vitro Diagnostics (IVD) Industry Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Vitro Diagnostics (IVD) Industry…

[healthcaremarketfmi]

Anatomic Pathology Market Opportunities, Threats, Drivers, Restraints, Trends, Applications, And Growth Forecast To 2030

The global anatomic pathology market forecast is set to reach US$ 61.1 Mn in revenues by 2030, according to a new market study by ESOMAR-certified market research firm, Future Market Insights (FMI).Anatomic Pathology Market Size (2022)US$ 32.5 MnAnatomic Pathology Market Revenue Forecast (2030)US$ 61.1 MnAnatomic Pathology Market Growth Rate (2022-2030)8.2% CAGRNorth America Market Share37.1%

The anatomic pathology market is subject to integrating medical informatics standards to meet specific healthcare requirements by curtailing costs and improvising on efficiency.

Pathology laboratories are on the verge of refurbishment as new-fangled disease diagnostic models are making a beeline therein.

As of now, lymphoma, breast cancer, colorectal cancer, prostate cancer, cervical cancer, and lung cancer are a part of anatomic pathology.

Key Takeaways

The instruments are subject to technological advancements, which would minimize errors. This factor is expected to drive the anatomic pathology market between 2022 and 2030

Consumables are expected to hold the largest market share due to low cost, high availability, and good purchase rate of probes and reagents

Academic research is bound to pick up pace in the forecast period owing to growing implementation of anatomic pathology in biomarker profiling and tumor examination

Preference to personalized therapies is prompting putative biomarkers being discovered. This factor is expected to be one of the key growth drivers

Key Participant Insights

The key market players are focusing on technological upgradations and expansion strategies to keep themselves fiercely competitive.

For instance –

In Jul 2020, Bio SB tabled its Fast Mohs PolyDetector Plus Detection System, which comes across as a super sensitive nonbiotin monovalent Fab micropolymer immunohistochemistry system to detect IVD antibodies for squamous cell carcinoma, basal cell carcinoma, and melanoma.

In Jan 2019, Quest Diagnostics announced completion of acquisition of the US laboratory services business that belonged to Oxford Immunotec (the T-Spot and Accutix tick-borne disease testing services, since then, are part of Quest’s infectious disease testing services.

In 2018, Leica Microsystems entered into a collaboration with Thermo Fisher to develop an integrated cryotomography workflow with regards to research.

For More information : https://www.futuremarketinsights.com/reports/anatomic-pathology-market

The other players in the veterinary imaging market include

Laboratory Corporation of America Holdings

Sakura Finetek USA, Inc.

F.Hoffmann-La Roche AG

Cardinal Health, Inc.

BioGenex

NeoGenomics

Agilent Technologies

The US continues to be one of the leading markets for anatomic pathology market globally. Strong presence of some of the leading players, combined with relatively easier funding for R&D will drive the US anatomic pathology market during the assessment period.

The Europe anatomic pathology market is also likely to grow at a brisk pace during the assessment period. The growth will remain concentrated in Western Europe, as has been the case traditionally.

Asia Pacific represents a high growth market for anatomic pathology stakeholders. Many countries in the region are renewing their focus on healthcare, as the current Covid-19 crisis has reinforced the necessity of a robust healthcare system.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global anatomic pathology market is segmented in detail to cover every aspect and present a complete market intelligence approach to the reader.

The study provides compelling insights on anatomic pathology market on the basis of product & services type (Instruments (Microtomes & Cryostat, Tissue processors, Automatic Stainers, and Other products), consumables (Reagents & Antibodies, Probes & Kits, and Others), application (Disease Diagnosis, Drug Discovery and Development, and Others), and services (histopathology, cytopathology)) across seven geographies.

Inquire Before Buying This Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-12370

Key Segments of Anatomic Pathology Industry Survey

Anatomic Pathology Market by Product & Service:

Anatomic Pathology Instruments

Anatomic Pathology Consumables

Anatomic Pathology Services

Anatomic Pathology Market by Application:

Disease Diagnosis

Drug Discovery and Development

Others

Anatomic Pathology Market by End User:

Hospitals

Research Laboratories

Diagnostic Laboratories

Others

[rohit890]

In Vitro Diagnostics (IVD) Quality Control Market Analysis, Demand & Forecast to 2020 – Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK)

Market Overview

The global in vitro diagnostics quality control market was valued at USD 1.5 billion in 2021 and it is anticipated to grow further up to USD 2.2 billion by 2031, at a CAGR of 3.7% during the forecast period.

The effectiveness of in vitro diagnostic tests, including those for pathogen identification using in vitro nucleic acid testing, healthcare-associated illnesses (HAIs) such as pneumonia, urinary tract infections, and others, is assessed using IVD quality controls. These products primarily concentrate on defect detection, quality control, and validation panels like the Blood Culture (BCID) Control Panel, Human Papillomavirus (HPV) Control Panel, and others to support in the implementation and monitoring of the performance of clinical and research laboratories, blood diagnostic centers, and IVD manufacturers.

View Detailed Report Description: https://www.globalinsightservices.com/reports/in-vitro-diagnostics-ivd-quality-control-market/

Market Dynamics

As the burden of various diseases increases globally, so has the number of laboratory tests. The number of laboratories in both the public and private sectors has increased in response to this need. With the start of the COVID-19 pandemic in December 2019, the demand for diagnostic tests has skyrocketed. Many government organizations have established new laboratories in response to this epidemic and to increase laboratory testing capacity. The majority of nations need clinical laboratories to get regulatory body accreditation before performing diagnostic tests. Additionally, accreditation to ISO 15189:2012 and other comparable standards is turning into a requirement in many nations. Authorities assess a laboratory’s competency and quality system during the accreditation process using predetermined standards. While some European nations, including Belgium, France, Hungary, Ireland, and Lithuania, require accreditation for a variety of laboratory tests, others, like Finland, the Netherlands, Sweden, Switzerland, and the UK, have practically finished the process.

It costs a lot of money to set up a QC process in a clinical laboratory. Additionally, laboratories must keep a specialized staff on hand to oversee the QC system. Moreover, regardless of the number of tests conducted, QC procedures are expensive. As a result, QC methods are particularly expensive to adopt for clinical laboratories that perform few diagnostic tests. This is predicted to lead to a lesser adoption of QC procedures, along with budgetary restrictions in many hospitals and laboratories in developed and emerging nations.

Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10301

The key players studied in the global in vitro diagnostic quality control market are Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), and Helena Laboratories Corporation (US) among others.

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1–833–761–1700

[aishavass]

The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...